Patent Number | Title | Applicant | Opposition Date |
---|---|---|---|
EP3626270 | New Use | NOVARTIS AG | Jun 25, 2024 |
EP3996688 | Pharmaceutical Preparation | MERCK PATENT GMBH | Jun 5, 2024 |
EP3345604 | Nalmefene For Reduction Of Alcohol Consumption In Specific Target Populations | H. LUNDBECK A/S | Mar 1, 2024 |
EP3294283 | Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure | NOVARTIS AG | Dec 7, 2023 |
EP3000467 | Treatment Regimen Utilizing Neratinib For Breast Cancer | WYETH LLC | Nov 28, 2023 |
EP3191461 | Crystalline Solid Forms Of 6-Carboxy-2-(3,5-Dichlorophenyl)-Benzoxazole | PFIZER INC. | Aug 3, 2022 |
EP3725778 | Formulations Of Enzalutamide | ASTELLAS PHARMA INC. | May 18, 2022 |
EP3434265 | Pharmaceutical Composition Containing Rifaximin Alpha & Delta | SANDOZ AG | Apr 6, 2022 |
EP2919766 | Sustained-Release Dosage Forms Of Ruxolitinib | INCYTE CORPORATION | Feb 28, 2022 |
EP2887961 | Nep Inhibitors For Treating Diseases Characterized By Atrial Enlargement Or Remodeling | NOVARTIS AG | Jan 26, 2022 |
Patent Number | Grant Date | Title | Total Oppositions |
---|---|---|---|
EP3785702 | Jul 20, 2022 | Microparticulate Varenicline Citrate | 1 |
EP3409272 | Jun 24, 2020 | Pharmaceutical Composition Comprising Eltrombopag Olamine, Reducing Sugar, And Polymeric Binder | 1 |
EP3395331 | Aug 21, 2019 | Pharmaceutical Tablet Composition Comprising Eltrombopag Olamine | 1 |
Feel free to send us a message here and we will get back to you